, Tracking Stock Market Picks
Enter Symbol:
Repros Therapeutics Inc. (RPRX) [hlAlert]

down 49.86 %

Repros Therapeutics Inc. (RPRX) upgraded to Buy by ROTH Capital

Posted on: Wednesday,  Nov 21, 2012  8:25 AM ET by Roth Capital

Roth Capital rated Buy Repros Therapeutics Inc. (NASDAQ: RPRX) on 11/21/2012, when the stock price was $14.36. Since
then, Repros Therapeutics Inc. has lost 49.86% as of 01/14/2016's recent price of $7.20.
If you would have followed this Roth Capital's recommendation on RPRX, you would have lost 49.86% of your investment in 1149 days.

Repros Therapeutics Inc. (RPRX) is a development-stage biopharmaceutical company focused on the development of oral small molecule drugs for unmet medical needs. The Company's principal drug, Proellex, is a selective blocker of the progesterone receptor and is being developed for the treatment of uterine fibroids, anemia associated with excessive menstrual bleeding relating to uterine fibroids, or anemia associated with uterine fibroids and endometriosis. The second product candidate, Androxal, is a single isomer of clomiphene citrate and an orally active small molecule compound.

ROTH researches emerging growth equities in the media, technology, telecommunications, healthcare, consumer, energy and industrial sectors. The research is focused on companies with market capitalization of between $100 million - $1 billion. Our coverage universe includes approximately 180 small cap growth companies around the globe including several companies from China. With an average market cap of approximately $500 million, our objective is to identify rapidly growing companies with significant long term growth prospects.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/21/2012 8:25 AM Buy
as of 12/31/2012
1 Week down  -0.75 %
1 Month up  4.93 %
3 Months up  9.67 %
1 YTD up  9.67 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/23/2009 8:55 PM Hold
2.73 4.00
12/5/2008 8:25 AM Buy
8.90 19.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy